Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Sep 24;79(1):59–64. doi: 10.1038/sj.bjc.6690012

Activity and regulation by growth factors of calmodulin-dependent protein kinase III (elongation factor 2-kinase) in human breast cancer

T G Parmer 1, M D Ward 1, E J Yurkow 2, V H Vyas 1, T J Kearney 1, W N Hait 1
PMCID: PMC2362180  PMID: 10408694

Abstract

Calmodulin-dependent protein kinase III (CaM kinase III, elongation factor-2 kinase) is a unique member of the Ca2+/CaM-dependent protein kinase family. Activation of CaM kinase III leads to the selective phosphorylation of elongation factor 2 (eEF-2) and transient inhibition of protein synthesis. Recent cloning and sequencing of CaM kinase III revealed that this enzyme represents a new superfamily of protein kinases. The activity of CaM kinase III is selectively activated in proliferating cells; inhibition of the kinase blocked cells in G0/G1-S and decreased viability. To determine the significance of CaM kinase III in breast cancer, we measured the activity of the kinase in human breast cancer cell lines as well as in fresh surgical specimens. The specific activity of CaM kinase III in human breast cancer cell lines was equal to or greater than that seen in a variety of cell lines with similar rates of proliferation. The specific activity of CaM kinase III was markedly increased in human breast tumour specimens compared with that of normal adjacent breast tissue. The activity of this enzyme was regulated by breast cancer mitogens. In serum-deprived MDA-MB-231 cells, the combination of insulin-like growth factor I (IGF-I) and epidermal growth factor (EGF) stimulated cell proliferation and activated CaM kinase III to activities observed in the presence of 10% serum. Inhibition of enzyme activity blocked cell proliferation induced by growth factors. In MCF-7 cells separated by fluorescence-activated cell sorting, CaM kinase III was increased in S-phase over that of other phases of the cell cycle. In summary, the activity of Ca2+/CaM-dependent protein kinase III is controlled by breast cancer mitogens and appears to be constitutively activated in human breast cancer. These results suggest that CaM kinase III may contribute an important link between growth factor/receptor interactions, protein synthesis and the induction of cellular proliferation in human breast cancer. © 1999 Cancer Research Campaign

Keywords: Ca2+/calmodulin-dependent protein kinase III (elongation factor-2 kinase), breast cancer, breast cancer mitogens, cell cycle, protein synthesis

Full Text

The Full Text of this article is available as a PDF (102.9 KB).

Footnotes

This work was supported by Grants CA 43888 and CA 57142 from the National Cancer Institute, and generous contribution from the Hyde and Watson Foundation

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bagaglio D. M., Hait W. N. Role of calmodulin-dependent phosphorylation of elongation factor 2 in the proliferation of rat glial cells. Cell Growth Differ. 1994 Dec;5(12):1403–1408. [PubMed] [Google Scholar]
  2. Celis J. E., Madsen P., Ryazanov A. G. Increased phosphorylation of elongation factor 2 during mitosis in transformed human amnion cells correlates with a decreased rate of protein synthesis. Proc Natl Acad Sci U S A. 1990 Jun;87(11):4231–4235. doi: 10.1073/pnas.87.11.4231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chafouleas J. G., Pardue R. L., Brinkley B. R., Dedman J. R., Means A. R. Regulation of intracellular levels of calmodulin and tubulin in normal and transformed cells. Proc Natl Acad Sci U S A. 1981 Feb;78(2):996–1000. doi: 10.1073/pnas.78.2.996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cheng E. H., Gorelick F. S., Czernik A. J., Bagaglio D. M., Hait W. N. Calmodulin-dependent protein kinases in rat glioblastoma. Cell Growth Differ. 1995 May;6(5):615–621. [PubMed] [Google Scholar]
  5. Fan H., Penman S. Regulation of protein synthesis in mammalian cells. II. Inhibition of protein synthesis at the level of initiation during mitosis. J Mol Biol. 1970 Jun 28;50(3):655–670. doi: 10.1016/0022-2836(70)90091-4. [DOI] [PubMed] [Google Scholar]
  6. Ford J. M., Prozialeck W. C., Hait W. N. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol. 1989 Jan;35(1):105–115. [PubMed] [Google Scholar]
  7. Futey L. M., Medley Q. G., Côté G. P., Egelhoff T. T. Structural analysis of myosin heavy chain kinase A from Dictyostelium. Evidence for a highly divergent protein kinase domain, an amino-terminal coiled-coil domain, and a domain homologous to the beta-subunit of heterotrimeric G proteins. J Biol Chem. 1995 Jan 13;270(2):523–529. doi: 10.1074/jbc.270.2.523. [DOI] [PubMed] [Google Scholar]
  8. Greenberg M. E., Hermanowski A. L., Ziff E. B. Effect of protein synthesis inhibitors on growth factor activation of c-fos, c-myc, and actin gene transcription. Mol Cell Biol. 1986 Apr;6(4):1050–1057. doi: 10.1128/mcb.6.4.1050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gschwendt M., Müller H. J., Kielbassa K., Zang R., Kittstein W., Rincke G., Marks F. Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun. 1994 Feb 28;199(1):93–98. doi: 10.1006/bbrc.1994.1199. [DOI] [PubMed] [Google Scholar]
  10. Hait W. N., DeRosa W. T. Calmodulin as a target for new chemotherapeutic strategies. Cancer Invest. 1988;6(5):499–511. doi: 10.3109/07357908809082118. [DOI] [PubMed] [Google Scholar]
  11. Hait W. N., Lazo J. S. Calmodulin: a potential target for cancer chemotherapeutic agents. J Clin Oncol. 1986 Jun;4(6):994–1012. doi: 10.1200/JCO.1986.4.6.994. [DOI] [PubMed] [Google Scholar]
  12. Hait W. N., Lee G. L. Characteristics of the cytotoxic effects of the phenothiazine class of calmodulin antagonists. Biochem Pharmacol. 1985 Nov 15;34(22):3973–3978. doi: 10.1016/0006-2952(85)90374-0. [DOI] [PubMed] [Google Scholar]
  13. Hait W. N., Ward M. D., Trakht I. N., Ryazanov A. G. Elongation factor-2 kinase: immunological evidence for the existence of tissue-specific isoforms. FEBS Lett. 1996 Nov 11;397(1):55–60. doi: 10.1016/s0014-5793(96)01140-4. [DOI] [PubMed] [Google Scholar]
  14. Levenson R. M., Blackshear P. J. Insulin-stimulated protein tyrosine phosphorylation in intact cells evaluated by giant two-dimensional gel electrophoresis. J Biol Chem. 1989 Nov 25;264(33):19984–19993. [PubMed] [Google Scholar]
  15. Lu K. P., Means A. R. Regulation of the cell cycle by calcium and calmodulin. Endocr Rev. 1993 Feb;14(1):40–58. doi: 10.1210/edrv-14-1-40. [DOI] [PubMed] [Google Scholar]
  16. MacManus J. P., Braceland B. M., Rixon R. H., Whitfield J. F., Morris H. P. An increase in calmodulin during growth of normal and cancerous liver in vivo. FEBS Lett. 1981 Oct 12;133(1):99–102. doi: 10.1016/0014-5793(81)80480-2. [DOI] [PubMed] [Google Scholar]
  17. Makino R., Hayashi K., Sugimura T. C-myc transcript is induced in rat liver at a very early stage of regeneration or by cycloheximide treatment. Nature. 1984 Aug 23;310(5979):697–698. doi: 10.1038/310697a0. [DOI] [PubMed] [Google Scholar]
  18. Mischak H., Goodnight J. A., Kolch W., Martiny-Baron G., Schaechtle C., Kazanietz M. G., Blumberg P. M., Pierce J. H., Mushinski J. F. Overexpression of protein kinase C-delta and -epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. J Biol Chem. 1993 Mar 25;268(9):6090–6096. [PubMed] [Google Scholar]
  19. Müller R., Bravo R., Burckhardt J., Curran T. Induction of c-fos gene and protein by growth factors precedes activation of c-myc. Nature. 1984 Dec 20;312(5996):716–720. doi: 10.1038/312716a0. [DOI] [PubMed] [Google Scholar]
  20. Palfrey H. C., Nairn A. C., Muldoon L. L., Villereal M. L. Rapid activation of calmodulin-dependent protein kinase III in mitogen-stimulated human fibroblasts. Correlation with intracellular Ca2+ transients. J Biol Chem. 1987 Jul 15;262(20):9785–9792. [PubMed] [Google Scholar]
  21. Parmer T. G., Ward M. D., Hait W. N. Effects of rottlerin, an inhibitor of calmodulin-dependent protein kinase III, on cellular proliferation, viability, and cell cycle distribution in malignant glioma cells. Cell Growth Differ. 1997 Mar;8(3):327–334. [PubMed] [Google Scholar]
  22. Prostko C. R., Zhang C., Hait W. N. The effects of altered cellular calmodulin expression on the growth and viability of C6 glioblastoma cells. Oncol Res. 1997;9(1):13–17. [PubMed] [Google Scholar]
  23. Rasmussen C. D., Means A. R. Calmodulin is involved in regulation of cell proliferation. EMBO J. 1987 Dec 20;6(13):3961–3968. doi: 10.1002/j.1460-2075.1987.tb02738.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rasmussen C. D., Means A. R. Calmodulin is required for cell-cycle progression during G1 and mitosis. EMBO J. 1989 Jan;8(1):73–82. doi: 10.1002/j.1460-2075.1989.tb03350.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Redpath N. T., Price N. T., Proud C. G. Cloning and expression of cDNA encoding protein synthesis elongation factor-2 kinase. J Biol Chem. 1996 Jul 19;271(29):17547–17554. [PubMed] [Google Scholar]
  26. Ryazanov A. G., Ward M. D., Mendola C. E., Pavur K. S., Dorovkov M. V., Wiedmann M., Erdjument-Bromage H., Tempst P., Parmer T. G., Prostko C. R. Identification of a new class of protein kinases represented by eukaryotic elongation factor-2 kinase. Proc Natl Acad Sci U S A. 1997 May 13;94(10):4884–4889. doi: 10.1073/pnas.94.10.4884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Watanabe T., Ono Y., Taniyama Y., Hazama K., Igarashi K., Ogita K., Kikkawa U., Nishizuka Y. Cell division arrest induced by phorbol ester in CHO cells overexpressing protein kinase C-delta subspecies. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10159–10163. doi: 10.1073/pnas.89.21.10159. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES